Hikma Pharma gains Middle East, North Africa rights to Aeterna's perifosine
This article was originally published in Scrip
Executive Summary
Aeterna Zentaris has inked a commercialisation and licensing agreement with Hikma Pharmaceuticals for its lead anticancer perifosine in the Middle East and North Africa regions.